BlackRock Inc. Takes Position in IQVIA Holdings Inc. $IQV

BlackRock Inc. bought a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 14,549,693 shares of the medical research company's stock, valued at approximately $2,811,292,000. BlackRock Inc. owned about 8.84% of IQVIA as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Apella Capital LLC increased its position in shares of IQVIA by 5.1% in the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company's stock valued at $211,000 after acquiring an additional 58 shares during the period. Quadrant Capital Group LLC lifted its holdings in IQVIA by 1.3% in the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company's stock worth $1,080,000 after buying an additional 60 shares during the period. Private Advisor Group LLC grew its position in shares of IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company's stock worth $1,163,000 after buying an additional 63 shares during the last quarter. Breakwater Capital Group grew its position in shares of IQVIA by 3.2% in the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company's stock worth $401,000 after buying an additional 64 shares during the last quarter. Finally, Keybank National Association OH increased its stake in shares of IQVIA by 0.7% during the fourth quarter. Keybank National Association OH now owns 9,103 shares of the medical research company's stock valued at $2,052,000 after buying an additional 67 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

Shares of IQVIA stock opened at $249.62 on Thursday. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $251.36. The firm has a market capitalization of $41.09 billion, a P/E ratio of 30.97, a P/E/G ratio of 2.04 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The business has a fifty day simple moving average of $210.23 and a two-hundred day simple moving average of $186.82.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts' consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the prior year, the firm earned $2.81 EPS. The company's revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a stock repurchase program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on IQV shares. Barclays reaffirmed an "overweight" rating on shares of IQVIA in a research note on Tuesday, July 28th. JPMorgan Chase & Co. upped their price objective on shares of IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. TD Cowen raised their target price on shares of IQVIA from $233.00 to $288.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. William Blair raised shares of IQVIA to a "strong-buy" rating in a research note on Tuesday, July 28th. Finally, BMO Capital Markets boosted their price target on shares of IQVIA from $210.00 to $270.00 and gave the company an "outperform" rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, IQVIA has an average rating of "Moderate Buy" and an average price target of $241.88.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the business's stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 12,913 shares of company stock worth $3,098,793 over the last three months. 1.70% of the stock is owned by corporate insiders.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source